Arrow Seldinger Arterial Catheterization Device Receives FDA Market Clearance
Designed for Risk Reduction, Optimal Performance, and Patient Safety
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced today that its Arrow® Seldinger Arterial Catheterization Device received market clearance from the U.S. Food and Drug Administration (FDA).
“As we continue to discover new and innovative solutions, the Seldinger Arterial Catheterization Device is now part of our extensive arterial offering in the U.S. market”
The new Seldinger Arterial Catheterization Device is indicated for short-term use. The device is designed to improve patient safety by eliminating confusion of catheter identification, reduce risk of complications associated with insertion technique, and provide optimal diagnostics leading to effective treatment for patients. Multiple sizes are available to provide customization to each patient, each insertion site, and each application.
“As we continue to discover new and innovative solutions, the Seldinger Arterial Catheterization Device is now part of our extensive arterial offering in the U.S. market,” said Jake Newman, Vice President and General Manager of Teleflex’s Vascular Access Division. “This innovative device is intended to facilitate ease of insertion and resistance to body collapse1.”
Teleflex expects to launch the Arrow® Seldinger Arterial Catheterization Device in the United States this year.
To learn more about the Arrow® Vascular portfolio from Teleflex, please visit teleflex.com/usa/product-areas/vascular-access/.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
References:
1. Teleflex. Seldinger Arterial Catheter Benchtop Studies. Data on File, D011453: 2014.
Teleflex, the Teleflex logo, and Arrow are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003596
Contacts
Teleflex Incorporated
Jake Elguicze, 610-948-2836
Treasurer and Vice President, Investor Relations
